Compare CNH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNH | CYTK |
|---|---|---|
| Founded | 1842 | 1997 |
| Country | United Kingdom | United States |
| Employees | 34197 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.4B |
| IPO Year | N/A | 2004 |
| Metric | CNH | CYTK |
|---|---|---|
| Price | $10.60 | $70.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $13.00 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 10.3M | 1.7M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $8.21 | $310.19 |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.00 | $31.99 |
| 52 Week High | $13.87 | $80.20 |
| Indicator | CNH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 46.76 |
| Support Level | $9.85 | $59.07 |
| Resistance Level | $11.13 | $70.69 |
| Average True Range (ATR) | 0.40 | 2.86 |
| MACD | -0.00 | -0.94 |
| Stochastic Oscillator | 53.47 | 30.07 |
CNH Industrial is the world's second largest manufacturer of agricultural machinery (82% of industrial net sales) as well as a major player in construction equipment (18% of industrial net sales). Its Case and New Holland brands have served farmers for generations. Geographically, agricultural sales are 40% in North America, 32% in Europe, the Middle East, and Africa, 18% in South America, and 10% in Asia-Pacific. CNH's products are available through a robust independent dealer network, which includes over 2,600 dealer and distribution locations and reach into 164 countries. The construction business leverages over 400 dealers. The company's captive finance arm provides retail financing to its customers and wholesale financing to dealers to maintain inventory, thereby supporting sales.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.